Compare NAVI & CTKB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NAVI | CTKB |
|---|---|---|
| Founded | 1973 | 1990 |
| Country | United States | United States |
| Employees | 670 | N/A |
| Industry | Investment Bankers/Brokers/Service | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 771.2M | 652.1M |
| IPO Year | N/A | 2021 |
| Metric | NAVI | CTKB |
|---|---|---|
| Price | $8.19 | $4.71 |
| Analyst Decision | Sell | Hold |
| Analyst Count | 7 | 5 |
| Target Price | ★ $12.14 | $5.70 |
| AVG Volume (30 Days) | ★ 860.0K | 702.7K |
| Earning Date | 04-29-2026 | 05-07-2026 |
| Dividend Yield | ★ 7.96% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $193,015,000.00 |
| Revenue This Year | $82.46 | $5.42 |
| Revenue Next Year | $12.45 | $7.03 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 17.67 |
| 52 Week Low | $7.86 | $2.37 |
| 52 Week High | $16.07 | $6.18 |
| Indicator | NAVI | CTKB |
|---|---|---|
| Relative Strength Index (RSI) | 31.15 | 61.68 |
| Support Level | $7.86 | $4.56 |
| Resistance Level | $8.40 | $5.24 |
| Average True Range (ATR) | 0.25 | 0.17 |
| MACD | 0.09 | 0.08 |
| Stochastic Oscillator | 37.50 | 96.25 |
Navient Corp provides technology-enabled education finance solutions that simplify complex programs and help millions of people achieve success. The company operates its business in two segments: Federal Education Loans, and Consumer Lending. A majority of its revenue is generated from the Federal Education Loans segment, in which the company owns and manages the Federal Family Education Loan Program (FFELP) loans, generating revenue mainly in the form of net interest income. The Consumer Lending segment owns and manages private education loans and is the master servicer for these portfolios. Through its Earnest brand, the company also refinances and originates in-school private educational loans.
Cytek Biosciences Inc is a cell analysis solutions company advancing the next generation of cell analysis tools by leveraging novel technical approaches. Its core instruments, the Cytek Aurora and Northern Lights systems, are the first full-spectrum flow cytometers able to deliver high-resolution, high-content, and high-sensitivity cell analysis by utilizing the full spectrum of fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells. Its FSP platform addresses the inherent limitations of other technologies by providing a higher density of information with greater sensitivity, more flexibility, and increased efficiency, all at a lower cost for performance. Geographically, the company generates a majority of its revenue from the United States.